ADAM23 Recombinant Rabbit mAb (SDT-3115-27)

ADAM23 is a member of the ADAM (A Disintegrin and Metalloproteinase) family of transmembrane proteins. Unlike many ADAMs, it is considered a "silent" or non-proteolytic member because its metalloproteinase domain is catalytically inactive due to key mutations. Its primary biological function stems from its disintegrin and extracellular domains, which mediate cell-cell and cell-matrix interactions by binding to integrins and other surface proteins, particularly within the nervous system. Biologically, ADAM23 is predominantly expressed in the brain and is crucial for neuronal development and synaptic function. It interacts with proteins like LGI1 (leucine-rich glioma-inactivated 1) to regulate synaptic transmission and neuronal excitability. Mutations in the ADAM23 gene have been linked to inherited epileptic disorders, highlighting its role in maintaining normal brain circuitry. The significance of ADAM23 extends to oncology, where it is frequently identified as a tumor suppressor. Its expression is often downregulated or silenced via promoter hypermethylation in various cancers, including glioblastoma, breast, and lung carcinomas. This loss is associated with increased tumor progression, metastasis, and poor patient prognosis. The protein's adhesive functions are believed to suppress malignancy by promoting stable cellular interactions and inhibiting migration. Furthermore, research suggests ADAM23 may influence signaling pathways that control cell proliferation and survival. Its role as a diagnostic or prognostic biomarker is being investigated, and understanding its precise mechanisms could inform novel therapeutic strategies for both neurological diseases and cancer, making it a protein of considerable translational interest.